TRACTION accelerates translation of discoveries into new clinical approaches
Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies, there remain many opportunities to improve outcomes for patients with cancer. Some may not benefit from available treatments, and others may have highly aggressive or drug-resistant cancers that require new options.
As part of MD Anderson’s commitment to bring our patients the most effective...
APOLLO’s high-quality longitudinal samples empower cancer investigators
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
Six MD Anderson researchers chosen for AAAS
In recognition of their contributions to basic, translational, and clinical research, six faculty members from MD Anderson Cancer Center have...
Chronic stress may promote resistance to lung cancer therapy
Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used to treat lung cancer patients with EGFR mutations, according to new research from MD Andrerson Cancer Center. Retrospective analysis of clinical patient data suggests that beta blockers may slow or prevent the development of resistance to EGFR inhibitors.
The research, published today...
What we can learn from revolutionary melanoma treatment
The largest analysis of metastatic melanoma patients who received a targeted therapy combination shows the treatment provides long-term survival...
Alliance formed to cure glioblastoma with personalized medicine
A new-generation clinical trial for glioblastoma multiforme (GBM) — the deadliest form of brain cancer – will begin enrolling patients by...
CLL survival greatly improved by ibrutinib
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated...
Why some drugs don’t work against pancreatic cancer
An MD Anderson study may explain why chemotherapy drugs such as gemcitabine are ineffective against pancreatic cancer in some patients. The...
This gene could unlock an immune attack on cancer
A team led by researchers at MD Anderson Cancer Center reports a crucial tumor-thwarting gene protects an immune attack against lung cancer...
Some colorectal cancers recur after treatment. But why?
Cetuximab, marketed as Erbitux®å, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients...